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Abstract
Endothelin-1 (ET-1) is a potent vasoconstrictor involved in the regulation of vascular tone and implicated in hypertension.
However, the role of small blood vessels endothelial ET-1 in hypertension remains unclear. The present study investigated
the effect of chronic over-expression of endothelial ET-1 on arterial blood pressure and vascular reactivity using transgenic
mice approach. Transgenic mice (TET-1) with endothelial ET-1 over-expression showed increased in ET-1 level in the
endothelial cells of small pulmonary blood vessels. Although TET-1 mice appeared normal, they developed mild
hypertension which was normalized by the ETA receptor (BQ123) but not by ETB receptor (BQ788) antagonist. Tail-cuff
measurements showed a significant elevation of systolic and mean blood pressure in conscious TET-1 mice. The mice also
exhibited left ventricular hypertrophy and left axis deviation in electrocardiogram, suggesting an increased peripheral
resistance. The ionic concentrations in the urine and serum were normal in 8-week old TET-1 mice, indicating that the
systemic hypertension was independent of renal function, although, higher serum urea levels suggested the occurrence of
kidney dysfunction. The vascular reactivity of the aorta and the mesenteric artery was altered in the TET-1 mice indicating
that chronic endothelial ET-1 up-regulation leads to vascular tone imbalance in both conduit and resistance arteries. These
findings provide evidence for the role of spatial expression of ET-1 in the endothelium contributing to mild hypertension
was mediated by ETA receptors. The results also suggest that chronic endothelial ET-1 over-expression affects both cardiac
and vascular functions, which, at least in part, causes blood pressure elevation.
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Introduction
Endothelin-1 (ET-1) is an endothelium-derived peptide with
vasoconstriction and mitogenic properties [1]. It exerts its
vasoconstrictor effect by binding to G-protein coupled receptors
(ETA or ETB) [2,3]. Intravenous injection of ET-1 leads to a
transient vasodilatation followed by a sustained increase in blood
pressure [4]. Blocking the maturation of ET-1 by intravenous
infusion of phosphoramidon lowers blood pressure in spontaneous
hypertensive rats (SHRs) [5]. ET-1 also contributes to hyperten-
sion in deoxycorticosterone acetate (DOCA)-salt hypertensive rats
and DOCA-salt treated SHRs [6–8], and ET receptor antagonists
(LU135252, A127722.5 and bosentan) had been shown to lower
blood pressure in various experimental hypertensive models [9–
12]. The arterial blood pressure elevation caused by ET-1 is
accompanied by structural and functional changes in small arteries
including vascular hypertrophy in different models of hypertension
[8,13]. These pharmacological analyses suggest that ET-1 plays an
important role in the pathogenesis of hypertension. However, it is
not clear whether these short-term elevation or reduction of ET-1
achieved by drug administration truly simulate the effect of
chronic effect of ET-1 under various pathological conditions.
Therefore, it is important to verify these studies using genetic
approaches to achieve long-term changes in ET-1. This will also
avoid the concern of potential side effects of the drugs.
ET-1 gene knockout mice were developed. Unfortunately, they
died soon after birth. Paradoxically, heterozygous ET-1 knockout
mice were hypertensive [14]. Transgenic mice that overexpress
human ET-1 (hET-1) or mouse ET-1 (mET-1) driven by their
respective promoters were normotensive even though their plasma
and tissue ET-1 levels were slightly elevated [15,16]. Both hET-1
and mET-1 transgenic mice developed renal cyst, interstitial
fibrosis and glomerulosclerosis. Salt-dependent hypertension was
observed in the older mET-1 mice, but it was attributed to the
consequence of renal damage [16]. Transgenic mice with tyrosine
kinase-2 (tie-2) promoter directed expression of human ET-1 in the
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vascular endothelium also exhibited normal arterial blood pressure
despite 7-fold increase in plasma ET-1 level. However, these mice
showed marked vascular hypertrophic remodeling accompanied
by increased production of reactive oxygen species (ROS) [17].
They also had increased inflammatory responses in the endothe-
lium [18]. The lack of hypertension in these ET-1 overexpressing
mice may be due to compensatory increased production of the
vasodilator NO, as suggested by the fact that introducing the hET-
1 transgene into the eNOS gene knockout mice caused further
increase in arterial blood pressure [19]. Nevertheless, the role of
ET-1 in the development of hypertension remains unclear.
We developed transgenic mice using the tyrosine kinase-1 (tie-1)
promoter [20] to drive the expression of mouse ET-1 cDNA
specifically in vascular endothelial cells. Unlike other ET-1
overexpressing mice described above, these transgenic (TET-1)
mice are hypertensive. In the present study we examined the effect
of increased ET-1 on vascular and cardiac functions in these mice.
Results
Circulating and Pulmonary ET-1 was Increased in TET-1
Mice
ET-1 peptide levels in the plasma, lung, heart, and kidney of the
8-week-old mice were determined by ELISA assays. Heterozygous
mice in both transgenic lines showed a small, but not significant
increase in plasma ET-1 levels (data not shown). However,
significant increases in the plasma ET-1 peptide levels were found
in the homozygous mice (*P,0.05) (Table 1). Therefore,
homozygous mice were used in all subsequent experiments. Both
lines of TET-1 mice showed significant increases in the ET-1
peptide levels in the lungs (**P,0.01) but not in the hearts or
kidneys. Such increases in the plasma and lung ET-1 levels
persisted in the 1-year-old TET-1 mice (data not shown).
To determine the cellular location of ET-1 mRNA expression in
the lung, brain and kidney, in-situ hybridization was performed
using labeled DNA probe which hybridizes to both endogenous
and transgene ET-1 mRNA (Fig. 1A). Endothelial specific ET-1
hybridization signal was found only in the small vessels of TET-1
lungs, and in the lung of non-transgenic (NTg) mice. No ET-1
mRNA expression was found in epithelial cells of the bronchial
structure, indicating that the ET-1 transgene was expressed
specifically in the endothelial cells.
Over-expression of Endothelial ET-1 Did Not Lead to
Fibrosis
In rats, monocrotaline induces pulmonary hypertension, collagen
V deposition and perivascular fibrosis, and these were thought to be
mediated by ET-1 [21]. To determine if over-expression of ET-1 in
the lungs of TET-1 mice would lead to similar pathologies, Masson
Trichrome staining was employed to examine sections of their lungs.
The lungs of 6 months old TET-1 mice did not exhibit any
abnormality in size, shape and structure of the alveoli (Fig. 1B1–2).
The pulmonary vascular and bronchiolar structures appeared normal
(Fig. 1B3–4) and there was no sign of perivascular fibrosis or excessive
collagen deposition. In addition, the coronary arteries had a similar
morphology to those of their NTg counterparts (Fig. 1B5–6).
TET-1 Mice Exhibited Hypertension that was Mediated by
ETA Receptors
To determine whether endothelial cells specific ET-1 over-
expression leads to blood pressure elevation, tail cuff measurement
was performed. TET-1 mice showed higher SBP and MBP
compared to the NTg counterparts. The diastolic blood pressure
was not significantly different (Fig. 2A).
We measured mean arterial blood pressure (MABP) of the 8
weeks old TET-1 mice using polyethylene pressure sensing
catheter. As shown in Figure 2B and 2C, MABP of the TET-1
mice was significantly higher than that of the NTg mice. To
determine the receptor subtype that mediates hypertension in the
TET-1 mice, the TET-1 and NTg mice were treated with ETA
and ETB receptor antagonists. Administration of ETA receptor
antagonist, BQ123 (1 mg/kg body weight) had no effect on the
MABP in NTg mice (Fig. 2A). On the other hand, MABP of the
TET-1 mice was reduced to the basal level of the NTg mice within
20 minutes of BQ-123 treatment. Administration of ETB receptor
antagonist, BQ788 had no effect on the blood pressure of TET-1
and NTg mice (Fig. 2C).
TET-1 Mice Developed Left Ventricular Hypertrophy
The left ventricle to total heart wet weight ratio in TET-1 mice
was 17% higher than that of their NTg littermates (P,0.001,
ANOVA) (Table 2). The left ventricle of both lines heterozygous
transgenic mice appeared normal (data not shown). For both lines
of transgenic TET-1 mice, the right ventricle to total heart wet
weight ratio was similar to that of NTg mice.
The electrocardiogram (ECG) showed that both lines of TET-1
mice had a left electrical axis deviation (Table 2). No arrhythmia was
observed. The atrial-ventricular conduction was found to be delayed
in the TET-1 mice. The P-R intervals of TET-1 mice (336 1.2 ms)
were significantly increased compared to their NTg littermates (266
1.6, *P,0.05, **P,0.01, ***P,0.001). The ratio of P-R/P-P
interval was significantly increased (P,0.05, ANOVA), indicating
delayed arterial-ventricular conduction in the TET-1 mice.
Kidney Function Analysis
Renal dysfunction is one of the hallmarks of hypertension. To
evaluate the renal function, urine and serum samples were
collected for solute measurement and clearance study. No
significant difference was observed in water and chow consump-
tion between different groups (Data not shown) Urinary
concentration of sodium, potassium, calcium and chloride ions
as well as urea and creatinine were not statistically different
between the NTg and TET-1 groups. The total amount of these
urinary solutes excreted in 24 hr was also the same in two groups.
However, it is noteworthy that higher levels of NO and urea were
found in the sera of TET-1 mice (Table 3).
Endothelium-dependent Vascular Function in TET-1 Mice
Endothelium-dependent relaxation to acetylcholine was signif-
icantly attenuated in both aorta and mesenteric artery of TET-1
Table 1. Endothelin-1 levels in plasma and various major
organs.
NTg TET-1
Plasma (pg/ml) 4.260.35 6.060.25*
Lung (pg/mg) 8.560.35 14.260.58**
Heart (pg/mg) 0.2460.01 0.2860.01
Kidney (pg/mg) 0.7460.05 0.7860.06
ET-1 peptide levels were measured by ELISA. Data are presented as means 6
SEM, N= 5. Statistically significant differences are shown as
*P,0.05,
**P,0.01, versus NTg control group.
doi:10.1371/journal.pone.0026994.t001
Endothelial ET-1 and Hypertension
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mice compared to the NTg mice (Fig. 3A, aorta: AUC,
274.4625.15 versus 193.5613.2, P,0.01; Fig. 3B, mesenteric
artery: AUC, 91.5868.03 versus 144.1617.6, respectively;
P,0.05). On the other hand, sodium nitroprusside-induced
endothelium-independent relaxations were not significantly differ-
ent between arteries of TET-1 and NTg mice (data not shown).
ET-1-induced contraction of the mesenteric artery were blunted
in the TET-1 mice compared to that of NTg mice (Fig. 3D,
mesenteric artery: AUC, 91.5868.03 versus 144.1617.6, respec-
tively; P,0.05) There was no significant difference between TET-
1 and NTG mice in ET-1 induced contraction of the aorta
(Fig. 3C). In the TET-1 aorta, but not the mesenteric artery,
phenylephrine-induced contraction was increased significantly
(Fig. 3E, aorta: AUC, 233.3615.41 versus 162.6617.58,
P,0.01). The TET-1 and NTG mice showed no difference in
their aorta and mesenteric artery’s response to thromboxane
agonist U46619 (data not shown).
Discussion
ET-1 is thought to contribute to increased arterial pressure in
several hypertensive animal models [13]. However, this is
primarily deduced from experiments with pharmacologically
manipulated short-term changes in ET-1 level. We therefore
Figure 1. ET-1 transcription and histology in TET-1 lung. (A) Bright-field micrographs of lung from NTg (1), 3771 TET-1 (2) demonstrated the
tissue morphologies. In dark field micrographs of lung from NTg (3), 3771 TET-1 (4), ET-1 mRNA expression is represented as white silver grain. A =
Alveoli; B = bronchiole; PA = pulmonary arteriole. Arrow in dark field shows ET-1 hybridization signal X 100 magnification. (B) Representative
micrographs of tissues stained for collagen deposit (blue) by Masson Trichrome staining including lung alveoli (1–2), pulmonary arterioles and
bronchioles (3–4) and heart (5–6). Qualitative observation indicated no obvious change in the sizes and structures of bronchioles, pulmonary arteries
among TET-1 and NTg groups (B = bronchiole; PA = pulmonary arteriole and CA= cardiac coronary artery) X 100 magnification, N= 5.
doi:10.1371/journal.pone.0026994.g001
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developed transgenic mice that overexpress ET-1 to simulate
chronic elevation of ET-1 in some pathological conditions. The tie-
1 promoter was used to drive the expression of mouse preproET-1
specifically in vascular endothelial cells. Two independent lines
(3771 and 3796) of TET-1 mice were investigated. Both lines
showed higher levels of ET-1 in their sera and lungs. The
increased ET-1 levels were still observed in the 1 year-old TET-1
mice indicating that the ET-1 transgene expression was main-
tained throughout adult live. The increase ET-1 expression in the
lungs of the TET-1 mice was confirmed by in situ hybridization
Figure 2. Elevated blood pressure in TET-1 mice. (A) Tail cuff measurement showed systolic blood pressure, mean blood pressure and diastolic
blood pressure of 8-week-old TET-1 mice and NTg counterparts (N= 12). (B and C) Mean arterial blood pressure (MABP) was measured with
polyethylene catheter in the right common carotid artery under anesthesia. (B) BQ-123 (1 mg/kg) and (C) BQ-788 (1 mg/kg) were injected
intraperitoneally at the time indicated by the arrows. The hypertension in TET-1 mice from line 3771 (B) was inhibited by BQ-123 but not by BQ788
(C). Means6SEM (mmHg), *P,0.05, **P,0.01, #P,0.0001 when compared to vehicle control group of the same genotype, N = 3.
doi:10.1371/journal.pone.0026994.g002
Endothelial ET-1 and Hypertension
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and ELISA. Despite the purported mitogenic and fibrotic effects of
ET-1 [22], we did not find fibrosis in TET-1 mouse lungs or any
structural abnormality in various main organs at age of 6 months
[23,24]. Both lines of mice exhibited higher MABP, which was
normalized by the administration of an ETA receptor antagonist
(BQ123) but not by the ETB antagonist (BQ788), indicating that
ET-1-induced hypertension in these mice was mediated by ETA
receptors. On the other hand, administration of BQ123 to the
NTg mice had no effect on their MABP, suggesting that ET-1 was
not involved in basal blood pressure regulation under normal
condition. This is in agreement with previous reports which
showed that systemic blood pressure in healthy humans was not
affected by BQ123 [25].
It is not clear why other ET-1 overexpressing mice previously
reported did not have increased MABP whereas TET-1 mice did.
The main difference is the promoter used to drive the expression
of ET-1. We used the tie-1 promoter which drives the expression
of ET-1 in the endothelial cells of small blood vessels only.
Transgenic ET-1 driven by the mouse or the human ET-1
promoter is likely to be expressed in wider range of tissues. Even
the tie-2 promoter is active in a wider range of cell types than tie-1
promoter. It is known to express transgenes in endothelial cells of
the arteries, veins and capillaries in various organs [26]. It is likely
that overexpression of ET-1 in some of these cells might induce
compensatory increased expression of vasodilator such as NO to
counteract the effect of increased level of ET-1. The fact that
MABP was increased in the heterozygous general ET-1 gene
knockout mice [14], and decreased in vascular endothelial cell-
specific ET-1 gene knockout mice [27], supports the notion that
certain cell types have feedback mechanisms to compensate for
increase/decrease ET-1 level.
The TET-1 mice showed left ventricular hypertrophy and a left
shift of the electrical axis in ECG analysis. These are not observed
in other ET-1 overexpressing transgenic mice that do not have
increased MABP and they are likely to be due to cardiac
remodeling as an adaptation to the higher MABP. Hypertension
in the TET-1 mice probably caused mild chronic overloading of
the heart. Increased dP/dt in TET-1 mice suggests load-
dependent increase of heart contractility in response to increased
vascular resistance. Increased heart contractility is often associated
with increased weight of the left ventricular wall. Left electrical
axis deviation seen in TET-1 mice suggests that there was a block
in impulse conduction. These mice also exhibited prolonged P-R
interval, often associated with essential hypertension and indicative
of a delay in depolarization from sinoatrial node to the ventricular
muscle [28]. These are indicators of mild heart diseases with no
immediate threat to life which explained why TET-1 mice did not
show early mortality. Despite higher level of ET-1 in the lungs of
TET-1 mice they did not have right ventricular hypertrophy,
suggesting no pulmonary hypertension.
Table 2. Physiological parameters of heart and
electrocardiography.
NTg TET-1
Body weight (g) 22.660.51 22.960.39
MABP (mmHg) 79.161.44 94.361.91**
Whole heart (mg) 128.164.81 133.563.90
LV/Hr (mg/mg) 0.3460.01 0.4060.01***
RV/Hr (mg/mg) 0.1760.01 0.1660.01
ECG
P-P (ms) 127.163.58 124.963.18
P-R (ms) 25.661.56 33.361.16**
P-R/P-P ratio 0.2160.02 0.2760.01*
QRS (ms) 7.060.29 7.860.25
Electrical axis (angle) 52.769.1 -14.8616.0**
Normal Left deviation
Body and heart weight (means6SEM) of TET-1 and NTg at 8-weeks old. Mean
arterial blood pressure (mmHg, means6SEM) of TET-1 and NTg mice. LV/Hr,
ratio of left ventricular wall wet weight to whole heart wet weight. RV/Hr, ratio
of left ventricular wall wet weight to whole heart wet weight. Left ventricular
walls of TET-1 were heavier than those of non-transgenic mice.
Electrocardiographic (ECG) profiles of TET-1 and non-transgenic (NTg) mice. P-P
and P-R intervals were calculated by time distance between respective peaks of
ECG tracings. QRS intervals were measured from beginning to end of the QRS
complex. P-R/P-P is the ratio of P-R interval to P-P interval. Electrical axis with
(0u)–(90u) is defined as normal, (21u)–(290u) is defined as left axis deviation.
TET-1 show increased P-R interval and left axis deviation. Values are expressed
in means6SEM, N= 9–12.
*P,0.05,
**P,0.01,
***P,0.001 (ANOVA), compared to NTg littermates. MABP – mean arterial
blood pressure, LV – left ventricle, RV – right ventricle, ECG – electrocardiogram.
doi:10.1371/journal.pone.0026994.t002
Table 3. Urine and serum solutes of euhydrated NTg and
TET-1 mice.
Sample and substance NTg TET-1
Urine Concentration
Osmolality (mmol/kg) 2817.66132.06 2690.76143.85
Na (mmol/L) 182.967.84 158.4612.87
K (mmol/L) 468.5621.32 465.1621.94
Ca (mmol/L) 2.7160.19 3.0160.17
Cl (mmol/L) 322.2615.43 292.6616.78
Urea (mmol/L) 1479.8680.10 1470.5680.79
Creatinine (mmol/L) 4716.56262.99 4593.66358.26
Serum Concentration
Osmolality (mmol/kg) 315.6461.89 323.365.19
NO (mM)(nitrate+nitrite) 27.1461.88 38.8662.9*
Na (mmol/L) 14460.81 144.960.60
K (mmol/L) 3.6260.11 3.760.14
Ca (mmol/L) 1.79260.06 1.81660.05
Cl (mmol/L) 110.1460.45 108.760.57
Urea (mmol/L) 6.9460.20 8.0360.27**
Creatinine (mmol/L) 13.5760.88 15.360.74
Urine 24 h excretion
Volume (ml) 1.0760.11 1.1260.88
Na (mmol) 0.1660.01 0.1460.01
K (mmol) 0.4260.019 0.4160.02
Ca (mmol) 0.002460.0002 0.002760.0001
Cl (mmol) 0.2960.013 0.2660.01
Urea (mmol) 1.3360.072 1.3260.07
Creatinine (mmol) 4.2460.23 4.1360.32
Urine and serum solutes of TET-1 and NTg mice. Values are means 6 SEM
(N= 15),
*P,0.05,
**P,0.01 compared with NTg mice.
doi:10.1371/journal.pone.0026994.t003
Endothelial ET-1 and Hypertension
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All three previous reported ET-1 overexpressing transgenic
mouse lines mice developed renal interstitial fibrosis, renal cysts,
and glomerulosclerosis, leading to reduced glomerular filtration
rate (GRF) [15,16]. These renal lesions were not observed in the
TET-1 mice. However, their serum urea levels were slightly
elevated, but creatinine clearance appeared normal. Together,
these suggest that the TET-1 mice may have very mild renal
dysfunction, but their elevated blood pressure was most likely not
of renal origin. The isolated arteries from these mice exhibited
blunted endothelium-dependent responses. This vascular dysfunc-
tion probably contributed to their hypertension.
It had been shown that chronic subcutaneous infusion of ET-1
increases acetylcholine-induced relaxation in the rat aorta [29]. By
contrast, in the TET-1 mice, the endothelium dependent
relaxation response in aorta was attenuated whereas the response
in smooth muscle was augmented. This dramatically illustrates the
different effects of raising plasma ET-1 level by different means.
Endothelial release of ET-1 in the TET-1 mice should be a better
model than subcutaneous infusion of ET-1 to simulate chronic
pathological increase of ET-1. Increased peripheral resistance is a
hallmark of essential hypertension attributed mainly to abnormal-
ities in small arteries [30,31]. The TET-1 mice, which overexpress
ET-1 specifically in the endothelial cells of small arteries,
developed hypertension. They should provide a good animal
model to investigate the role of ET-1 in the pathogenesis of
hypertension.
Materials and Methods
Animals
The generation of TET-1 mice was reported earlier [32].
Transgenic animals and their wild-type littermates were kept
under controlled conditions at a temperature of 20oC and housed
under diurnal light condition. They were fed on standard rodent
chow and water ad libitum, and unless specified otherwise, were
used for experiments at the age of 8 weeks. The use of animals in
this study was conducted according to the requirements of the
Cap. 340 Animal (Control of Experiments) Ordinance and
Regulations, and all relevant legislation and Codes of Practice in
Hong Kong. All the experimental and animal handling procedures
were approved by the Committee of the Use of Live Animals in
Teaching and Research in The University of Hong Kong (Permit
number #634-01).
Quantitative Measurement and Localization of ET-1
Expression in The Lung
In situ hybridization was performed as described [33] on tissues
of 8 weeks old TET-1 mice to determine the site of transgene
expression. Levels of plasma and tissue ET-1 peptide were assessed
by ELISA using an ET-1 enzyme immunoassay kit RPN 228
(Amersham, Buckinghamshire, U.K.) as described. [34].
General Histology and Masson-Trichrome Staining for
Collagen
Heart, lung and kidney tissues were collected from 6-month-old
mice. The tissues were embedded in paraffin and the dewaxed
slides were first immersed in Weigert’s hematoxylin (Sigma, St.
Louis, MO, U.S.A.). They were stained serially with acid fuschin,
phosphomolybdic acid and methyl blue. The color was fixed in
1% acetic acid. Then the slides were dehydrated using increasingly
higher concentration of alcohol, fixed in toluene, mounted in
Permount (Fisher Scientific, U.S.A.) and air-dried overnight before
observation and photography [35]. The nuclei appear as blue-
Figure 3. Vascular reactivity in aortas and mesenteric arteries of 8 weeks old TET-1 mice. Cumulative concentration-response curves to (A
and D) acetylcholine (ACh), (B and E) ET-1 and (C and F) Phe. Relaxations are percent decrease in tension during contractions to phenylephrine.
Contractions are percent reduction in lumen. (A to C) Aortic segments and (D–F) mesenteric artery in response to ACh, ET-1 and Phe in TET-1mice and
NTg littermates. Results are Means6SEM, N=8–10. *P,0.05.
doi:10.1371/journal.pone.0026994.g003
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black while the cytoplasm, muscle fibers and red blood cells were
stained red and the collagen fibers stained blue. The stained
sections were viewed and photographed with a light microscope
(Axiophot, Zeiss, Germany) using bright-field and/or dark-field
illumination.
Systemic Blood Pressure Measurement
Eight weeks old male mice were anesthetized with urethane
(1.8 mg/g body weight) and the body temperature was maintained
at 37.0 – 38.0uC on a heating pad with automatic temperature
control (FHC, Bowdoinham, ME, U.S.A.). The mean arterial
blood pressure was monitored continuously by cannulating the
right common carotid artery with a polyethylene catheter
connected to a saline-filled pressure transducer (Model 1050BP,
UFI, Morro Bay, CA, U.S.A.) for one hour. Heart rate and mean
arterial blood pressure data were analyzed using the PowerLab 8 s
software (ADinstruments, NSW, Australia). To determine the
direct hemodynamic effects of the selective ETA/ETB receptor
antagonist BQ123/BQ788 (Peninsula Co., San Carlos, CA,
U.S.A.) on basal mean arterial blood pressure (MABP), the drugs
were administered (1 mg/kg) intraperitoneally (100 ml). Control
groups were injected with 100 ml saline. After drug administration,
MABP was continuously monitored and recorded for 30 minutes.
Tail Cuff Blood Pressure Measurement
Blood pressure was determined in conscious animals using a
non-invasive computerized automated tail-cuff system (Vistech
BP-2000 Blood Pressure Analysis System; Vistech Systems; Apex,
NC). The mice were trained by placing them in restrainers for 15
minutes daily for five consecutive days before determining their
blood pressure. On the day of measurement, the animals were
placed on a heated platform and underwent 10 preliminary cycles.
The average of three 10-cycle measurements, which each have a
minimum of 6 out of 10 successful measurement cycles, was used
for data analysis. BP-2000 software calculated the systolic (SBP)
and diastolic (DBP) blood pressure.
Electrocardiogram (ECG)
Electrocardiographic recordings were acquired from a single
channel ECG recorder (Cardisuny 501B, Fukuda M-E, Japan)
with the filter, sensitivity set at 2 cm/mV, and at 50 mm/s speed.
The mice were anesthetized using Hypnorm & Hyponorval
mixture (fentanyl citrate 0.394 mg/kg, fluanisone 12.5 mg/kg and
midazolam 6.25 mg/kg) and were placed on a heating plate to
maintain body temperature around 37.0–38.0uC. One electrode
was placed at the base of each limb using subcutaneous platinum
pins. Signals was amplified and recorded by a PowerLab 8s system
(ADinstruments, New South Wales, Australia). Recordings were
made for 10 seconds and twice, each for leads I, II, III, aVR, aVL
and aVF. The P-P and P-R time intervals were determined by
measuring the distances between respective peaks of the ECG
waves. Three consecutive beat intervals in lead I were sampled
and averaged. Heart rate was derived from the P-P interval. Only
data with the heart rate between 400-600 beats per min were
accepted [36]. The electrical axis was determined by two-
dimensional vector ECG. The algebraic sums of voltage
amplitudes of the QRS complex in lead I and III were used to
calculate the degree of shift of the electrical axis.
Heart Wet Weight
Hearts were removed, and washed in cold PBS to remove excess
blood. The major blood vessels and the adhering fat were
removed. The whole hearts were blotted and weighed. The
ventricles were cut free from the atria. The left and right ventricles
were separated from the septum. Then the atria, ventricles and
septum were blotted again, and their wet mass was recorded to the
nearest 0.1 mg on an electronic balance [37].
Evaluation of Renal Function
Individual mice were put into a metabolic cage to measure
water/chow consumption, urine output and to collect urine
sample (Nalgene, U.S.A.). Serum samples were collected by
cardiac puncture under anesthesia (ketamine/xylazine). Serum
Na, K, Ca, Cl, urea and creatinine were measured by means of a
Hitachi-747 Autoanalyzer (Boehringer-Mannheim, Mannheim,
Germany). Serum nitric oxide level was measured with Griess
reagent assay (Cayman Chemical, Ann Arbor, MI, U.S.A.). Urine
Na, K, Ca, Cl, urea and creatinine were measured with a
Synchron CX5 Analyzer (Beckman Instruments, Inc., Fullerton,
CA, USA). Urine osmolality was measured by the vapor pressure
method using a Wescor Vapro vapor pressure osmometer (Wescor
Inc., Logan, Utah, USA). The creatinine clearance was used as an
index of glomerular filtration rate and was calculated from the
formula: creatinine clearance= urinary creatinine x urine volume/
serum creatinine.
Functional Studies on Isolated Arteries
Mice were anesthetized with ketamine/xylazine. The abdom-
inal aortae and the second branch mesenteric arteries with
adjacent tissue were collected and placed in ice-cold physiolog-
ical salt solution (Krebs solution of the following composition
(mM): NaCl 119, KCl 4.7, CaCl2 2.5, MgCl2 1, KH2PO4 1.2,
NaHCO3 25 and glucose 11). The adhering fat was removed
and the arteries were cut into segments of 2 mm in length. The
rings were suspended between two tungsten wires with a
diameter of 40 mm for aortae and 25 mm for mesenteric arteries
in an organ chamber filled with control solution and oxygenated
with 95%O2 and 5% CO2 to give a pH value between 7.3–7.5.
The organ chamber was maintained at 37uC using a built-in
heat exchanger. One of the tungsten wires was connected to a
movable holder supporting a tension transducer so that
isometric force measurement could be collected by a data
acquisition system (PowerLab 4SP, ADInstruments, U.S.A.). An
optimal basal tension of 3mN for aortae and 1 mN for
mesenteric arteries was applied and the arteries were allowed
to equilibrate at this baseline tone for 90 minutes. After
stabilization, the segments were exposed to KCl (60 mmol/L)
twice for contraction control. Endothelium-dependent and -
independent relaxations were assessed by measuring decrease in
tension caused by cumulative doses of acetylcholine (ACh,
1 nmol/L to 10 mmol/L) and sodium nitroprusside (SNP,
10 nmol/L to 0.1 mmol/L) during contraction to phenylephrine
(3 mmol/L). Contractions were evoked with ET-1 (0.1 nmol/L
to 0.1 mmol/L) and phenylephrine (10 nmol/L to 10 mmol/L).
Statistical Analysis
Data are presented as means 6 standard error of mean (SEM)
with N being the number of individual observations. Statistical
analysis was performed using Prism 4.0 software (Graphpad, San
Diego, CA, U.S.A.) and Statview 5.0 software (SAS Institute,
Cary, NC, U.S.A.). Numerical data sets from all experiments were
analyzed using the Mann-Whitney U-test for two groups
comparison and One-way ANOVA for multi-groups comparison,
as appropriate. The area under each dose-response curves was
estimated and statistical significance between the areas under
curves of different datasets was analysed using Student’s t-test for
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comparison of two groups. P values less than 0.05 was considered
to indicate statistically significant difference.
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